Aug 2026· Journal of Controlled Release· pp.
115238
· 0 citations· 51 references
Medicine
TL;DR
It is reported that horseradish peroxidase (HRP) can catalyze artemisinin to generate ROS, and a "ROS bomb" nanomedicine was designed for antitumor immunotherapy, offering a potent approach for treating deep-seated tumors.
Abstract
Conventional reactive oxygen species (ROS)-mediated tumor therapies such as photo-, sono-, and chemodynamic therapies are often limited by inadequate penetration depth of external stimuli and insufficient endogenous ROS substrates (e.g., O₂ and H₂O₂). Here, we report that horseradish peroxidase (HRP) can catalyze artemisinin to generate ROS. Based on this, a "ROS bomb" nanomedicine was designed for antitumor immunotherapy. The nanocarrier consists of silica cross-linked micelles incorporating ROS-cleavable thioketal bonds and encapsulated artemisinin as the payload, with surface-immobilized HRP serving as the trigger. Within the tumor microenvironment with elevated H₂O₂, the thioketal linkers are cleaved to release artemisinin, initiating an HRP-catalyzed ROS cascade. The ROS burst induces immunogenic cell death and activates the STING pathway in dendritic cells assisted by the co-released drug SN38, effectively suppressing the growth of immunosuppressive triple-negative breast tumors. This exogenous ROS delivery strategy overcomes the restrictions of conventional ROS therapies, offering a potent approach for treating deep-seated tumors.
BIMLM is developed as a biomimetic nanoplatform integrating lactate oxidase (LOX)-driven lactate exhaustion with MnO2-coated IR-780 for TME remodeling and self-amplifying ROS generation that enhances PDT/CDT efficacy while triggering metabolic starvation and ferroptosis, which collectively enable tumor eradication.
Bo-Ye Zhang, Yu-Li Chen, Pengyan Qiao et al.· Journal of Advanced Research· 0 citations
Tumor hypoxia critically drives the development of an immunosuppressive tumor microenvironment (TME) and accelerates tumor progression. Besides, hypoxia seriously restricts O2-dependent reactive oxygen species (ROS) generation, thereby severely compromising the therapeutic efficacy of photodynamic therapy (PDT). To a...
Chen-Lu Huang, Han-Yong Wang, Xin-Yu Yang et al.· ACS Nano· 0 citations
The synergistic combination of radiotherapy (RT) and photothermal therapy (PTT) holds great promise for cancer treatment, yet its efficacy is severely hampered by tumor hypoxia, insufficient reactive oxygen species (ROS) generation, and lack of precise imaging guidance. Herein, we develop bovine serum albumin (BSA)-bio...
Rui-Ying Zhang, Miao-Qing Li, Rui Cao et al.· Journal of materials chemist...· 0 citations
Ferroptosis, a regulated cell death pathway driven by iron-dependent lipid peroxidation, has emerged as a promising strategy for cancer therapy. Nevertheless, the direct delivery of iron can lead to systemic toxicity. In this study, a nonferrous ferroptosis-like strategy employing 2D Ti3C2 MXene nanosheets was develope...
This hydrogel-nanoparticle composite platform helps overcome photothermal therapy-induced immune suppression, reduce oxidative stress in the TME, and inhibit tumor metastasis, offering a promising strategy for enhancing cancer immunotherapy.
Jie Sun, Yun-Yun Wu, Sheng Zhao et al.· ACS Applied Materials and In...· 0 citations
Although low-dose radiotherapy (LDRT) exhibits high potential for radiotherapy, it meets a cascade of limitations for effectively eradicating refractory tumors due to low cell-killing effects, insufficient reactive oxygen species (ROS) production and acquired radio-resistance. Here, we engineered a new type of self-oxy...
Hong-Lian Yu, Jing Liu, Jun-Jie Wang et al.· Biomaterials· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.